DDInter1098 DDInter1652
Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Lovastatin {u} (Compound) resembles {v} (Compound) Pravastatin
Lovastatin {u} (Compound) treats {v} (Disease) atherosclerosis
Lovastatin {u} (Compound) binds {v} (Gene) UGT2B7
Lovastatin {u} (Compound) upregulates {v} (Gene) C2CD2
Lovastatin {u} (Compound) downregulates {v} (Gene) UTP18
Lovastatin {u} (Compound) causes {v} (Side Effect) Vertigo
Lovastatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Liothyronine
Lovastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Elotuzumab
Lovastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pegaspargase
Lovastatin {u} may lead to a major life threatening interaction when taken with {v} Lenalidomide
Lovastatin (Compound) resembles Pravastatin (Compound)
Lovastatin (Compound) treats atherosclerosis (Disease)
Lovastatin (Compound) binds UGT2B7 (Gene)
Lovastatin (Compound) upregulates C2CD2 (Gene)
Lovastatin (Compound) downregulates UTP18 (Gene)
Lovastatin (Compound) causes Vertigo (Side Effect)
Lovastatin may cause a minor interaction that can limit clinical effects when taken with Liothyronine
Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase
Lovastatin may lead to a major life threatening interaction when taken with Lenalidomide